<DOC>
	<DOCNO>NCT01608555</DOCNO>
	<brief_summary>The study include 10 adult patient cystic fibrosis . The aim study evaluate whether Tobramycin 300 mg aerosol once-a-day 28 day reduce bacterial load airway . Secondary end-point evaluation variation bacterial susceptibility end study period .</brief_summary>
	<brief_title>Tobramycin 300 mg Once-a-day ( o.d . ) Aerosol Adults With Cystic Fibrosis</brief_title>
	<detailed_description>Ten adult patient cystic fibrosis enrol stable phase receive prophylaxis aerosol Tobramycin 300 mg day 28 day .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Outpatients , male female , age range 1845 year Diagnosis cystic fibrosis FEV1 &gt; 50 % predict . sputum sample available Chest x ray negative pneumonia tuberculosis Informed consent Allergy tobramycin Use systemic steroid previous 2 week Pregnancy breast feeding Treatment experimental drug previous 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>bacterial load</keyword>
	<keyword>inhale tobramycin</keyword>
</DOC>